Los “cócteles” de medicamentos combinados para tratar la infección por VIH son una parte importante de la rutina de los pacientes, permitiéndoles reducir la cantidad de píldoras que deben tomar cada día. Pero las tabletas para salvar vidas también fueron el foco de los esquemas anticompetitivos del fabricante de medicamentos contra el VIH líder en la nación, Gilead Sciences, de acuerdo con una demanda del consumidor presentada el martes.
Featured News
UK Competition Watchdog Probes Into OCS’s £3.1 Billion Mitie Deal
Nov 18, 2026 by
CPI
Booking to Challenge EU Court Ruling Blocking $1.79B Etraveli Deal
Nov 18, 2026 by
CPI
Newsmax Sues to Block Fox-Roku Integration After $22 Billion Deal
Nov 18, 2026 by
CPI
Tesla, Hertz and Uber Face Antitrust Suit Over $4.2B Electric-Vehicle Deal
Nov 18, 2026 by
CPI
Simpson Thacher Adds Five Partners to Litigation Practice
Nov 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner